These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37960239)

  • 1. Neuroimaging Insights: Kava's (
    Savage K; Sarris J; Hughes M; Bousman CA; Rossell S; Scholey A; Stough C; Suo C
    Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.
    Savage KM; Stough CK; Byrne GJ; Scholey A; Bousman C; Murphy J; Macdonald P; Suo C; Hughes M; Thomas S; Teschke R; Xing C; Sarris J
    Trials; 2015 Nov; 16():493. PubMed ID: 26527536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.
    Sarris J; Stough C; Bousman CA; Wahid ZT; Murray G; Teschke R; Savage KM; Dowell A; Ng C; Schweitzer I
    J Clin Psychopharmacol; 2013 Oct; 33(5):643-8. PubMed ID: 23635869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study.
    Sarris J; Byrne GJ; Bousman CA; Cribb L; Savage KM; Holmes O; Murphy J; Macdonald P; Short A; Nazareth S; Jennings E; Thomas SR; Ogden E; Chamoli S; Scholey A; Stough C
    Aust N Z J Psychiatry; 2020 Mar; 54(3):288-297. PubMed ID: 31813230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?
    Sarris J; Teschke R; Stough C; Scholey A; Schweitzer I
    Planta Med; 2011 Jan; 77(2):107-10. PubMed ID: 20814850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of kava (Piper methysticum) on peripheral gene expression among individuals with generalized anxiety disorder: A post hoc analysis of a randomized controlled trial.
    Cribb L; Sarris J; Savage KM; Byrne GJ; Metri NJ; Scholey A; Stough C; Bousman CA
    Phytother Res; 2023 Dec; 37(12):5897-5903. PubMed ID: 37767766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of kava in the treatment of anxiety disorders.
    Singh YN; Singh NN
    CNS Drugs; 2002; 16(11):731-43. PubMed ID: 12383029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kava for Generalized Anxiety Disorder: A Review of Current Evidence.
    Ooi SL; Henderson P; Pak SC
    J Altern Complement Med; 2018 Aug; 24(8):770-780. PubMed ID: 29641222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice.
    Garrett KM; Basmadjian G; Khan IA; Schaneberg BT; Seale TW
    Psychopharmacology (Berl); 2003 Oct; 170(1):33-41. PubMed ID: 12845414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects.
    Sarris J; Stough C; Teschke R; Wahid ZT; Bousman CA; Murray G; Savage KM; Mouatt P; Ng C; Schweitzer I
    Phytother Res; 2013 Nov; 27(11):1723-8. PubMed ID: 23348842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kava (Piper methysticum) Extract for the Treatment of Nervous Anxiety, Tension and Restlessness.
    Kuchta K; Hladikova M; Thomsen M; Nahrstedt A; Schmidt M
    Drug Res (Stuttg); 2021 Feb; 71(2):83-93. PubMed ID: 33207379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.
    Sarris J; Kavanagh DJ; Byrne G; Bone KM; Adams J; Deed G
    Psychopharmacology (Berl); 2009 Aug; 205(3):399-407. PubMed ID: 19430766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum.
    Sarris J; Kavanagh DJ; Adams J; Bone K; Byrne G
    Complement Ther Med; 2009 Jun; 17(3):176-8. PubMed ID: 19398072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled study of Kava kava in generalized anxiety disorder.
    Connor KM; Davidson JR
    Int Clin Psychopharmacol; 2002 Jul; 17(4):185-8. PubMed ID: 12131602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piper methysticum (kava kava).
    Altern Med Rev; 1998 Dec; 3(6):458-60. PubMed ID: 9855570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kava: a comprehensive review of efficacy, safety, and psychopharmacology.
    Sarris J; LaPorte E; Schweitzer I
    Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kava in generalized anxiety disorder: three placebo-controlled trials.
    Connor KM; Payne V; Davidson JR
    Int Clin Psychopharmacol; 2006 Sep; 21(5):249-53. PubMed ID: 16877894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kava and its Kavalactones Inhibit Norepinephrine-induced Intracellular Calcium Influx in Lung Cancer Cells.
    Botello JF; Corral P; Bian T; Xing C
    Planta Med; 2020 Jan; 86(1):26-31. PubMed ID: 31711251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients.
    Boerner RJ; Sommer H; Berger W; Kuhn U; Schmidt U; Mannel M
    Phytomedicine; 2003; 10 Suppl 4():38-49. PubMed ID: 12807341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kava consumption and its health effects.
    Gounder R
    Pac Health Dialog; 2006 Sep; 13(2):131-5. PubMed ID: 18181402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.